Albany Medical Center
Home / Caring / Educating / Find a Doctor / News / Give Now / Careers / About / Calendar / Directions / Contact
Physician Finder Maps & Directions


Milt Teitler , Ph.D.


1978 - Ph.D. from University of Toronto
1976 - University of Buffalo

Current Research

Many drugs that effect human mood and/or thought act by mimicking or inhibiting the actions of neurons in the brain. Nerves function by releasing chemicals (neurotransmitters) that interact with sites (receptors) on other neurons in the brain. An important type of neuron in the brain produces and releases the substance serotonin; serotonin interacts with "serotonin receptors" located on other neurons adjacent to the serotonin-producing neuron. Dr. Teitler has established the role of serotonergic systems in control of mood and cognition as well as the serotonergic mechanisms of anti-migraine, anti-nausea, anti-psychotic, and hallucinogenic drugs. Dr. Teitler is currently pursuing the discovery of novel drugs directed at serotonin receptors and their functions in the brain and periphery. Underlying Dr. Teitler's research program is a belief that the receptor multiplicity for all neuroactive substances will lead to new insights into biological systems and to the development of new and/or improved drug therapies for all diseases. Site-specific mutagenesis to produce mutant forms of serotonin receptors in vitro has revealed novel properties of antipsychotic drugs: this work has potential implications for uncovering the etiology of mental diseases and for the development of novel antipsychotic medications. Recently important anti-psychotic drugs, such as risperidone (Risperdal), have been found to produce unique effects on cells expressing serotonin receptors. The exploration of these unique effects are revealing a new class of drugs, novel molecular mechanisms for receptor regulation, and the possibility of a new class of therapeutics for many diseases. In addition, the understudied properties of the "5-HT1E" receptor, discovered in Dr. Teitler's laboratory, are being explored with an emphasis on the development of the first drugs designed to selectively stimulate or block this receptor. These drugs should aid in understanding the function of the 5-HT1E receptor and may have novel therapeutic properties.

For publications listed in PubMed:


  1. Jessica A Knight, Carol Smith, Nicole Toohey, Michael T. Klein, and Milt Teitler. Pharmacological analysis of the novel, rapid and potent inactivation of the human 5-HT7 receptor by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol. Pharmacol.,in press (2008)

  2. Carol Smith, Tariq Rahman, Nicole Toohey, Joseph Mazurkiewicz, Katharine Herrick-Davis, and Milt Teitler, Risperidone Irreversibly Binds to and Inactivates the h5-HT7 Serotonin Receptor, Mol. Pharmacol., 70(4):1264-70, (2006).

  3. Anil Purohit, Carol Smith, Katharine Herrick-Davis, and Milt Teitler. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. Psychopharmacology, 179: 461-469(2005)

  4. Dukat M, Smith C, Herrick-Davis K, Teitler M, Glennon RA.Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation.Bioorg Med Chem. 12:2545-52(2004)

  5. M. Teitler M, Herrick-Davis K, Purohit A.Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem. 2002 Jun;2(6):529-38 (2002).

  6. Milt Teitler, Nicole Toohey, Jessica A. Knight, Michael T. Klein, Carol Smith. Clozapine and other competitive antagonists reactive risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions